Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Uncategorized

BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $129

BMO Capital analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $127 to $129.

byBenzinga Newsdesk

May 3, 2021

1 minute read

BMO Capital analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $127 to $129.

Smith & Nephew Stock Is Trading Lower Despite Posting Surge In Q2 Revenues, Profit

By Vandana Singh

Today, 6:45 AM

Smith & Nephew Plc (NYSE:SNN) revenues soared in Q2 as COVID-19 restrictions eased and levels of elective surgery returned towards normal…

SNN

Truist Securities Initiates Coverage On Nike with Buy Rating, Announces Price Target of $190

By Benzinga Newsdesk

Today, 6:45 AM

Truist Securities analyst Beth Reed initiates coverage on Nike (NYSE:NKE) with a Buy rating and announces Price Target of $190.

NKE

Trades See Even More Upside To Nike Shares

By Craig Jones

Today, 6:45 AM

Shares of Nike Inc (NYSE: NKE) Thursday spiked almost 5% after JPMorgan analysts said in a note to clients that the footwear and apparel leader expects China sales to grow.

NKE

Needham Maintains Buy on Compass, Lowers Price Target to $7

By Benzinga Newsdesk

Today, 6:45 AM

Needham analyst Mayank Tandon maintains Compass (NYSE:COMP) with a Buy and lowers the price target from $13 to $7.

COMP

BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $129

Related Posts

Smith & Nephew Stock Is Trading Lower Despite Posting Surge In Q2 Revenues, Profit

Truist Securities Initiates Coverage On Nike with Buy Rating, Announces Price Target of $190

Trades See Even More Upside To Nike Shares

Needham Maintains Buy on Compass, Lowers Price Target to $7